NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
20
DYN Quote, Financials, Valuation and Earnings
Last price:
$23.91
Seasonality move
:
12.85%
Day range:
$23.65 - $24.90
52-week range:
$12.06 - $47.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.46x
Volume:
1.5M
Avg. volume:
1M
1-year change:
104.87%
Market cap:
$2.4B
Revenue:
--
EPS (TTM):
-$3.56
Analysts' Opinion
-
Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Dyne Therapeutics has an estimated upside of 110.16% from its current price of $23.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $23.99.
Fair Value
-
According to the consensus of 0 analysts, Dyne Therapeutics has 110.16% upside to fair value with a price target of -- per share.
DYN vs. S&P 500
-
Over the past 5 trading days, Dyne Therapeutics has underperformed the S&P 500 by -4.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dyne Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dyne Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Dyne Therapeutics reported revenues of --.
Earnings Growth
-
Dyne Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Dyne Therapeutics reported earnings per share of -$0.96.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$182.8M | -$214.6M | -$314.5M | -$62.3M | -$105.7M | |
| EBITDA | -$181.2M | -$212.9M | -$312.8M | -$61.8M | -$105.2M | |
| Diluted EPS | -$3.50 | -$3.59 | -$3.56 | -$0.99 | -$0.96 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $379.8M | $424.7M | $258.2M | $168.2M | $736.4M | |
| Total Assets | $381.5M | $466.9M | $299.7M | $205.2M | $768.8M | |
| Current Liabilities | $4.7M | $23.4M | $23.3M | $29.7M | $43.3M | |
| Total Liabilities | $14.6M | $52.8M | $49.9M | $53.2M | $63.3M | |
| Total Equity | $366.8M | $414.1M | $249.7M | $152M | $705.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$152.5M | -$182.3M | -$243M | -$50.6M | -$74.6M | |
| Cash From Investing | $67.7M | $76.4M | -$161.9M | $12.8M | -$19.4M | |
| Cash From Financing | $276K | $91.4M | $806.4M | $454K | $18M | |
| Free Cash Flow | -$157.1M | -$183.5M | -$244.4M | -$50.8M | -$74.9M | |
DYN
Sector
Market Cap
$2.4B
$43.9M
Price % of 52-Week High
50.56%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
104.87%
-29.11%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$25.49
200-day SMA
Sell
Level
$32.64
Bollinger Bands (100)
Sell
Level
27.94 - 40.34
Chaikin Money Flow
Buy
Level
27.3M
20-day SMA
Sell
Level
$27.76
Relative Strength Index (RSI14)
Sell
Level
32.85
ADX Line
Sell
Level
9.45
Williams %R
Buy
Level
-94.3941
50-day SMA
Sell
Level
$29.64
MACD (12, 26)
Sell
Level
-1.52
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
15.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Stock Forecast FAQ
In the current month, DYN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DYN average analyst price target in the past 3 months is --.
-
Where Will Dyne Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dyne Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Dyne Therapeutics?
Analysts are divided on their view about Dyne Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dyne Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Dyne Therapeutics's Price Target?
The price target for Dyne Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DYN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dyne Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DYN?
You can purchase shares of Dyne Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dyne Therapeutics shares.
-
What Is The Dyne Therapeutics Share Price Today?
Dyne Therapeutics was last trading at $23.91 per share. This represents the most recent stock quote for Dyne Therapeutics. Yesterday, Dyne Therapeutics closed at $23.99 per share.
-
How To Buy Dyne Therapeutics Stock Online?
In order to purchase Dyne Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
